Primary Biliary Cholangitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Primary Biliary Cholangitis therapeutics.
Synopsis
- In 2022, there will be more than 500,000 diagnosed prevalent cases of PBC across 16 pharmaceutical markets.
- There are three leading marketed products for the treatment of PBC, Intercept Pharmaceuticals is a key player in the disease space.
- The PBC pipeline consists of 30 pharmaceutical therapies spanning all stages of development, with approximately 90% of drugs in mid-to-early-stage development.
- Intercept Pharmaceuticals dominate clinical trial development in PBC, with the US emerging as the key country for conducting trials in PBC.
- Deals involving acquisitions were the most common type of deals in the US relating to companies involved in developing PBC assets.
- Therapeutic options for PBC patients continue to be limited, with only one new therapy expected to reach the market during the next 18 months.
GlobalData’s Primary Biliary Cholangitis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Primary Biliary Cholangitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Primary Biliary Cholangitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Key Findings
- Disease Overview
- Epidemiology Overview
- Epidemiology Overview: Total Diagnosed Prevalent Cases of PBC in 2022 and 2027
- Treatment Overview
- Treatment Guidelines
- Marketed Drugs Assessment
- Marketed Drugs – Leading Marketed Drugs in PBC
- Marketed Drugs – Overview by Mechanism of Action
- Marketed Drug Profile: Intercept’s Ocaliva
- Pricing and Reimbursement Assessment
- Marketed Drugs – Manufacturer Price ($/mg)
- Marketed Drugs – Time to Pricing and Reimbursement
- Pipeline Drugs Assessment
- Pipeline Drugs Overview – Mid-to-Late-Stage Pipeline Drugs in PBC
- Pipeline Drugs – Overview by Development Stage
- Pipeline Drugs – Overview by Molecule Type
- Pipeline Drugs – Overview by Mechanism of Action
- Pipeline Drugs – Overview by Route of Administration
- Pipeline Drugs – Drug-Specific PTSRs and LoA in Primary Biliary Cholangitis
- Pipeline Drugs – Phase Transition Success Rates and Likelihood of Approval in Gastrointestinal Therapy Area and in Primary Biliary Cholangitis
- Clinical Trials Assessment
- Clinical Trials in PBC – Historical Overview
- Clinical Trials in PBC – Overview by Phase
- Clinical Trials in PBC – Overview by Status
- Clinical Trials in PBC – Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in PBC – Trials with a Virtual Component
- Clinical Trials in PBC – Geographic Overview
- Clinical Trials in PBC – Single-Country and Multinational Trials by Region
- Clinical Trials in PBC – Top 20 Sponsors with Breakdown by Phase
- Clinical Trials in PBC – Top 20 Sponsors with Breakdown by Status
- Clinical Trials in PBC – Overview by Endpoint Status
- Clinical Trials in PBC – Overview by Race and Ethnicity
- Clinical Trials in PBC – Enrollment Data
- Clinical Trials in PBC – Overview of Sites by Geography
- Clinical Trials in PBC – Top 20 Countries for Trial Sites
- Clinical Trials in PBC – Top 20 Sites Globally
- Clinical Trials – Feasibility Analysis: Geography Overview
- Clinical Trials – Feasibility Analysis: Benchmark Models for Primary Biliary Cholangitis
- Deals Landscape
- Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in PBC by Region
- Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in PBC
- Commercial Assessment
- Commercial Assessment – Key Market Players in Primary Biliary Cholangitis
- Future Market Catalysts
- Future Market Catalysts – Upcoming Market Catalysts in PBC
- Appendix
- Methodology
- Methodology – Sales Forecasts
- Methodology – Pricing and Reimbursement
- Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook